Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Amgen’s evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia... Learn More
Join us live on October 22, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
This exciting one-day seminar provides attendees with a unique opportunity to hear in-depth analysis of hot topics and trends concerning global biosimilars while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
October 1, 2014
Physicians Value Long-Acting and FDC Antidiabetic Agents, Although Competitive Pricing Will Be Needed for Favorable Reimbursement
September 30, 2014
Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents
September 25, 2014
While Physicians are Receptive to Emerging Antibiotics For Drug-Resistant Gram-Negative Infections, Payers Expect to Limit Hospital Use of Novel Premium-Priced Agents
September 23, 2014
Similarities in Key Global Markets Allow Pharma to Leverage Payer Value Messaging in Multiple Countries Through “Country Archetypes” Approach
What Market Access Challenges and Opportunities Lie Ahead for Emerging SLE Biologics?
Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50... Read More
Sweden: Market Access Tracker - 2014
Last Updated 30 September 2014Although Sweden’s pharmaceutical market is relatively small compared... Read More
Crohn's Disease - 2014
Last Updated 29 September 2014
Treatment options for Crohn’s disease (CD) include conventional, largely... Read More